BICO Group AB (publ) CLLKF
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BICO Group AB (publ) is a Sweden-based life science tools and biotechnology company focused on bioconvergence, combining biology, engineering, software, and automation technologies to support pharmaceutical, biotechnology, and academic research customers. The company develops and supplies instruments, consumables, and software used in areas such as cell biology, tissue engineering, diagnostics, laboratory automation, and bioprinting. BICO operates primarily within the broader life sciences and laboratory technology industries, with revenue generated through equipment sales, recurring consumables, software, and service contracts.
The company was founded in 2016 in Gothenburg, Sweden, originally under the name CELLINK, with an early focus on 3D bioprinting technologies and bioinks for tissue engineering applications. Through a series of acquisitions and expansion initiatives, the company broadened its portfolio into laboratory automation, biosciences, and medical technology and rebranded as BICO in 2021. Its strategic positioning centers on enabling automated and digitally integrated laboratory workflows for drug discovery, cell-based research, and precision medicine applications.
Business Operations
BICO conducts operations through multiple business areas that historically have included Bioprinting, Biosciences, and Bioautomation, though reporting structures have evolved over time through restructuring and portfolio optimization initiatives. The company generates revenue from hardware systems, laboratory instruments, recurring consumables, maintenance services, and software platforms. Key technologies include 3D bioprinters, microfluidics systems, live-cell imaging tools, single-cell analysis systems, and automated laboratory workflow solutions. BICO maintains a diversified customer base consisting of pharmaceutical companies, biotechnology firms, academic research institutions, and clinical laboratories.
The company operates internationally with commercial activities across Europe, North America, and parts of Asia-Pacific. BICO controls a portfolio of specialized life science subsidiaries, including CELLINK, CYTENA, Nanoscribe, Scienion, and MatTek, among others acquired during its expansion phase. These subsidiaries contribute proprietary technologies in areas such as high-precision bioprinting, single-cell dispensing, microfabrication, tissue models, and advanced imaging. The company has also entered collaborative relationships with pharmaceutical and research organizations to integrate automation and digital biology tools into laboratory workflows.
Strategic Position & Investments
BICO’s strategic direction has focused on building an integrated life science tools platform centered on automation, digitalization, and advanced cell biology research. The company has pursued growth through acquisitions intended to expand technological capabilities and diversify end markets beyond bioprinting. Major acquisitions have included Nanoscribe GmbH, known for high-precision 3D microfabrication technologies; MatTek Corporation, specializing in advanced in vitro tissue models; and Scienion AG, focused on precision dispensing technologies for diagnostics and life science applications. Public filings and investor communications indicate that BICO has also undertaken restructuring and cost-efficiency programs in response to changing market conditions and capital allocation priorities.
The company remains active in emerging sectors tied to regenerative medicine, laboratory automation, synthetic biology, and precision diagnostics. Its technologies are positioned to support trends toward automated research environments and personalized medicine workflows. BICO has emphasized software-enabled laboratory integration and scalable automation capabilities as part of its long-term strategic vision. Some public disclosures regarding future profitability targets and portfolio optimization initiatives have evolved over time; therefore, certain long-term operational outcomes remain dependent on market execution and are not fully verifiable from current public sources.
Geographic Footprint
BICO is headquartered in Gothenburg, Sweden, and maintains operations, subsidiaries, and commercial activities across multiple global markets. The company has a significant operational presence in Sweden, Germany, and the United States, with additional customer reach throughout Europe, North America, and parts of Asia-Pacific. Its international structure reflects the geographic distribution of acquired businesses and research-focused customer markets.
The company’s technologies are used by universities, pharmaceutical companies, and research laboratories globally. Through subsidiaries such as MatTek in the United States and Nanoscribe in Germany, BICO maintains localized production, research, and commercial operations that support both regional and international customers. Its global footprint is closely tied to life science research spending and pharmaceutical innovation centers.
Leadership & Governance
BICO was co-founded by Erik Gatenholm, who became widely associated with the company’s early development in bioprinting and bioconvergence technologies. The company is publicly listed in Sweden and operates under a corporate governance framework aligned with Swedish public company standards and reporting requirements. Leadership communications have consistently emphasized innovation-driven growth, decentralized subsidiary operations, and long-term investment in life science automation technologies.
Key executives and leadership figures have included:
- Erik Gatenholm – Co-Founder and Chief Executive Officer
- Héctor Martínez – Chief Financial Officer
- Maria Forss – Chief People Officer
- Lars Gatenholm – Co-Founder and board-related leadership roles historically associated with company development
Public company disclosures indicate that management has focused on integrating acquired businesses, improving operational efficiency, and strengthening recurring revenue streams through consumables and software-enabled services. Certain executive roles and organizational structures have changed periodically as part of broader restructuring initiatives and strategic realignment efforts.